Tradestie Institutional Equity Comparison Engine

MESO vs ABCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while MESO counters with relative strength in Growth & Margin. Fundamentally, MESO trades at N/M Forward P/E with -42.6% operating margin (+390.7% YoY revenue) versus ABCL at 27.6x Forward P/E and -1550.0% operating margin (-76.3% YoY). In options structure, MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro) against ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
MESO N/M vs ABCL 27.6x Fwd P/E
Growth & Margin Winner MESO
Op Margin -42.6% vs -1550.0% ยท YoY +390.7% vs -76.3%
Momentum & Technical Winner ABCL
1Y -16.4% vs +209.0% ยท 52W Pos 6% vs 69%
Options & Structure Winner ABCL
UNCLASSIFIED (37th %ile IV) vs CONSOLIDATION (25th %ile IV)
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
1M Return -5.21%
1Y Return +208.98%
Forward P/E 27.6x
Unified AI Score
60.7 / 100 BUY
Tech 52.0 Fund 59.0 Flow 67.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MESO -16.42% ABCL +208.98% Spread: +225.4 pp (ABCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MESO TTM Op. Margin: -42.6% ABCL TTM Op. Margin: -1550.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs ABCL. Trailing 12-month operating profitability (MESO -42.6% vs ABCL -1550.0%) and valuation multiples (MESO N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MESO (5) vs ABCL (5)
Institutional Metric MESO ABCL Criterion Row Winner
Market Capitalization Scale $1.7B $3.8B Larger Scale ABCL
Trailing P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio Valuation N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY) Growth +390.7% -76.3% Higher Growth MESO
Operating Margin (TTM) Profitability -42.6% -1550.0% Higher Margin MESO
Net Profit Margin Profitability -47.8% -248.8% Higher Margin MESO
Return on Equity (ROE) Capital Efficiency -9.9% -17.3% Higher ROE MESO
52-Week Range Position Momentum 6% ($12โ€“$22) 69% ($3โ€“$15) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 78% Vol 2.31ฮฒ ยท 87% Vol Lower Realized Risk MESO
Unified Institutional Score Composite Signal 34.6 / 100 (SELL) 60.7 / 100 (BUY) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MESO vs ABCL Buy Guide
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MESO nor ABCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.